Reseña o resumen
Sarcopenia is common in older men and women, and yet awareness of its clinical relevance is still relatively low. Only formally included in the International Classification of Diseases in 2016, the condition may impact societies with serious health-related and financial consequences unless consistent, effective methods of identification and management are adopted.
This second edition of Sarcopenia provides geriatricians and other healthcare professionals with a revised and expanded examination of this understudied and underdiagnosed condition. Edited by two leading authorities on the subject, it covers the epidemiology and diagnosis of sarcopenia, as well as treatment options and possible prevention strategies. Eight newly written chapters build upon existing knowledge with fresh data on topics including sarcopenia's biomarkers and its impact on the healthcare economy. This important text:
Defines sarcopenia and explains its clinical relevance
Covers all recent scientific evidence
Outlines treatment options
Considers prevention strategies
Discusses sarcopenia as a public health priority
Features eight new chapters covering topics such as sarcopenia's clinical management, its biomarkers, and its financial impact
Containing vital information for clinicians and other professionals working in geriatric care, nursing homes, nutrition, cancer, endocrinology, surgery, sports medicine and many other specialties, Sarcopenia, second edition, is a groundbreaking and essential new resource.
List of Contributors vii
Preface xiii
1 Definitions of Sarcopenia 1
Alfonso J. Cruz-Jentoft, Beatriz Montero-Errasquin and John E. Morley
2 Epidemiology of Muscle Mass Loss with Age 11
Marjolein Visser
3 The Role of Mitochondria in Age-Related Sarcopenia 19
Luigi Ferrucci, Marta Zampino, Paul Coen and Bret H. Goodpaster
4 Motor Unit Remodeling 35
Ben Kirk and Mathew Piasecki
5 Nutrition, Protein Turnover and Muscle Mass 45
Stéphane Walrand, Christelle Guillet and Yves Boirie
6 Recognizing Persons at Risk for Sarcopenia 63
John E. Morley
7 Adverse Outcomes and Functional Consequences of Sarcopenia 71
Jean Woo
8 A Lifecourse Approach to Sarcopenia 77
Richard Dodds and Avan Aihie Sayer
9 Acute Sarcopenia 95
Beatrice Gasperini, Stefano Volpato and Antonio Cherubini
10 Sarcopenia, Frailty, and Intrinsic Capacity 115
Jurgen M. Bauer and Cornel Sieber
11 Osteosarcopenia 127
Ben Kirk, Jesse Zanker, Steven Phu and Gustavo Duque
12 Sarcopenic Obesity 147
Mauro Zamboni, Federica Macchi, Nicole Nori and Andrea P. Rossi
13 Sarcopenia and Cognitive Impairment 157
Liang-Kung Chen
14 Sarcopenia and Other Chronic Organ Diseases 175
Hidenori Arai
15 Imaging of Skeletal Muscle 185
Thomas F. Lang
16 Measurements of Muscle Mass, Equations and Cut-off Points 199
Marjolein Visser and Laura Schaap
17 Deuterated Creatine Dilution to Assess Muscle Mass (D3-Cr Muscle Mass) in Humans: Methods, Early Results, and Future Directions 227
Peggy M. Cawthon and William J. Evans
18 Measurement of Muscle Strength and Power 239
Michael Drey, Sandra Helmers and Jürgen M. Bauer
19 Measurements of Physical Performance 253
Laura Orlandini, Yves Rolland and Matteo Cesari
20 Biomarkers for Physical Frailty and Sarcopenia: A Two-Body Problem 271
Anna Picca, Riccardo Calvani and Emanuele Marzetti
21 Quality of Life and Sarcopenia 279
Charlotte Beaudart, Jean-Yves Reginster, Olivier Bruyère and Anton Geerinck
22 Exercise Interventions to Prevent and Improve Sarcopenia 305
Mark D. Peterson and Jose A. Serra
23 Nutritional Approaches to Treat Sarcopenia 335
Tommy Cederholm, Jurgen M. Bauer and Alfonso J. Cruz-Jentoft
24 Beta-hydroxy-beta-methylbutyrate (HMB) and Sarcopenia 355
Francesco Landi, Riccardo Calvani, Anna Picca and Emanuele Marzetti
25 The Future of Drug Treatments 367
Francesco Landi, Graziano Onder and Rolland Yves
26 Sarcopenia: Is It Preventable? 403
Stany Perkisas, Keliane Liberman, Ivan Bautmans and Maurits Vandewoude
27 Financial Impact of Sarcopenia 421
Kristina Norman
28 Sarcopenia Management for Clinicians 433
Renuka Visvanathan and Solomon Yu
Index 441